ExpreS2ion Biotech Holding AB - Asset Resilience Ratio
ExpreS2ion Biotech Holding AB (EXPRS2) has an Asset Resilience Ratio of 5.64% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read EXPRS2 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2023)
This chart shows how ExpreS2ion Biotech Holding AB's Asset Resilience Ratio has changed over time. See ExpreS2ion Biotech Holding AB (EXPRS2) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ExpreS2ion Biotech Holding AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ExpreS2ion Biotech Holding AB (EXPRS2) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr4.44 Million | 5.64% |
| Total Liquid Assets | Skr4.44 Million | 5.64% |
Asset Resilience Insights
- Limited Liquidity: ExpreS2ion Biotech Holding AB maintains only 5.64% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ExpreS2ion Biotech Holding AB Industry Peers by Asset Resilience Ratio
Compare ExpreS2ion Biotech Holding AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for ExpreS2ion Biotech Holding AB (2018–2023)
The table below shows the annual Asset Resilience Ratio data for ExpreS2ion Biotech Holding AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 5.64% | Skr4.44 Million ≈ $477.49K |
Skr78.69 Million ≈ $8.47 Million |
+6.75pp |
| 2022-12-31 | -1.12% | Skr-1.53 Million ≈ $-164.87K |
Skr137.36 Million ≈ $14.78 Million |
-68.09pp |
| 2021-12-31 | 66.97% | Skr101.77 Million ≈ $10.95 Million |
Skr151.96 Million ≈ $16.35 Million |
+67.79pp |
| 2020-12-31 | -0.81% | Skr-966.00K ≈ $-103.96K |
Skr118.86 Million ≈ $12.79 Million |
+4.17pp |
| 2019-12-31 | -4.99% | Skr-933.00K ≈ $-100.41K |
Skr18.71 Million ≈ $2.01 Million |
-1.73pp |
| 2018-12-31 | -3.25% | Skr-682.00K ≈ $-73.39K |
Skr20.95 Million ≈ $2.25 Million |
-- |
About ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a biotechnology company, develops vaccines and biologics products to address critical unmet medical needs in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2. It is also developing ES2B-I002, a cytomegalo… Read more